glp-1 news today cardiovascular outcomes 2025 november The Many Cardiovascular Benefits of GLP-1 Drugs

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms in: Journal of Endocrinology Volume 263 Issue 1 (2024)

20.77

★★★★☆4.8 (126)

GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

24.85

★★★★★4.9 (98)

Cardiac Trials | Lowering CV risk in diabetes with GLP1 agonism? This large trial showed both improved outcomes — which in combo with LEADER Trial

22.54

★★★★★5.0 (157)

GLP-1 Studies Add to Growing Body of Evidence Demonstrating Significant Benefit on Cardiovascular Outcomes

21.81

★★★★★4.7 (84)

GLP-1 medications are known for their weight-loss effects, but fewer people may know that they could benefit the heart too. In fact, Wegovy was approved by the FDA to reduce the risk

21.31

★★★★★4.9 (203)

Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes | Cardiovascular Diabetology

22.62

★★★★★5.0 (176)

GLP-1 trends 2025: real-world data, patient outcomes & future therapies

29.35

★★★★★4.8 (132)